Skip to main content

Table 2 Multivariate logistic regression analysis of factors predictive of vascular invasion in patients with positive seral HbsAg

From: Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma

Variables Odds ratio 95% CI P value
Risk of vascular invasion
 Age (>50 years vs < =50 years) 0.68 0.44–1.04 0.078
 Alpha-fetoprotein (> 20 ng/ml vs < = 20 ng/ml) 2.51 1.59–3.96 <0.01*
 Tumor number (Multiple vs Single) 2.18 1.04–4.55 0.038*
 Diameter (> 3 cm vs < = 3 cm) 1.73 1.04–2.88 0.035*
 Edmonson grading (Grades III/IV vs Grades I/II) 2.48 1.21–5.05 0.013*
 Tumor capsule (Incomplete/absent vs Complete) 2.17 1.25–3.77 0.006*
 Seral HBeAg (Positive vs Negative) 1.83 1.10–3.03 0.019*
 Seral HBV DNA load (> 50 IU/ml vs < = 50 IU/ml) 1.68 1.06–2.65 0.027*
Risk of microscopic vascular invasion
 Alpha-fetoprotein (> 20 ng/ml vs < = 20 ng/ml) 2.59 1.65–4.05 <0.01*
 Tumor number (Multiple vs Single) 2.21 1.09–4.51 0.028*
 Diameter (> 3 cm vs < = 3 cm) 1.58 0.96–2.61 0.074
 Edmonson grading (Grades III/IV vs Grades I/II) 2.24 1.11–4.54 0.024*
 Tumor capsule (Incomplete/absent vs Complete) 2.04 1.18–3.51 0.011*
 Seral HBeAg (Positive vs Negative) 1.59 0.98–2.57 0.059
 Seral HBV DNA load (> 50 IU/ml vs < = 50 IU/ml) 1.76 1.12–2.76 0.013*
Risk of portal vein tumor thrombus
 DCP (>100 mAU/ml vs < = 100 mAU/ml) 2.90 1.17–7.12 0.022*
 Tumor diameter (>3 cm vs < =3 cm) 8.86 2.67–29.39 <0.01*
 Tumor capsule (Incomplete/absence vs Complete) 3.59 1.56–8.25 0.003*
 Seral HBeAg (Positive vs Negative) 1.67 1.01–2.75 0.046*
 Anti-virus treatment (Yes vs No) 0.59 0.33–1.05 0.075
  1. CI Confidential Interval; HBeAg Hepatitis B virus e Antigen; HBV Hepatitis B virus; DCP Des-gamma-carboxy prothrombin; HBsAg Hepatitis B virus s Antigen; HBeAg Hepatitis B virus e Antigen
  2. *P < 0.05